(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 32.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Harmony Biosciences Holdings's revenue in 2023 is $400,760,000.On average, 4 Wall Street analysts forecast HRMY's revenue for 2023 to be $34,920,659,263, with the lowest HRMY revenue forecast at $32,529,746,614, and the highest HRMY revenue forecast at $40,952,839,282. On average, 3 Wall Street analysts forecast HRMY's revenue for 2024 to be $45,814,861,913, with the lowest HRMY revenue forecast at $39,149,585,640, and the highest HRMY revenue forecast at $56,992,305,883.
In 2025, HRMY is forecast to generate $55,159,393,465 in revenue, with the lowest revenue forecast at $46,427,849,516 and the highest revenue forecast at $71,762,376,829.